Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNotes PayablesPayablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Quantumzyme (QTZM) Cash & Equivalents (2016 - 2026)

Quantumzyme (QTZM) has 6 years of Cash & Equivalents data on record, last reported at $184.0 in Q4 2025.

  • For Q4 2025, Cash & Equivalents fell 96.37% year-over-year to $184.0; the TTM value through Oct 2025 reached $184.0, down 96.37%, while the annual FY2025 figure was $584.0, N/A changed from the prior year.
  • Cash & Equivalents reached $184.0 in Q4 2025 per QTZM's latest filing, down from $584.0 in the prior quarter.
  • Across five years, Cash & Equivalents topped out at $5068.0 in Q4 2024 and bottomed at $184.0 in Q4 2025.